Skip to main content
Article thumbnail
Location of Repository

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers

By Jens J Kort, Stella Aslanyan, Joseph Scherer, John P Sabo, Veronika Kohlbrenner and Patrick Robinson

Abstract

The use of HIV protease inhibitors (PIs) as part of antiretroviral therapy in the treatment of HIV-1 infection may be associated with an increased risk of bleeding. This prospective, randomized, open-label trial in healthy volunteers compared the effects of tipranavir/ritonavir (TPV/r), darunavir/ritonavir (DRV/r), and ritonavir (RTV) alone on platelet aggregation after a single dose and at steady-state concentrations. Subjects were selected on the basis of normal platelet aggregation and arachidonic acid (AA)-induced platelet aggregation inhibition after administration of a single 325-mg dose of aspirin. All 3 PI therapies were administered twice daily for 10 days

Topics: Article
Publisher: Bentham Science Publishers Ltd
OAI identifier: oai:pubmedcentral.nih.gov:3343416
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). Acquired immunodeficiency syndrome and the risk of stroke. Stroke
    2. (1999). Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia
    3. (2001). Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage.
    4. (2008). Coagulation factor levels are not affected by tipranavir (TPV/r) capsules or vitamin E-containing solution formulations nor by comparator protease inhibitors (PI).
    5. (2000). Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    6. (2008). Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets
    7. (2006). Drug Administration: Important safety information: Intracranial hemorrhage in patients receiving Aptivus (tipranavir) capsules.
    8. (2008). Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis
    9. (2002). Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
    10. (1998). Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection.
    11. (2007). Evaluation of intracranial hemorrhage in 49,610 HIV-infected veterans and California Medicaid recipients.
    12. (2006). Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis
    13. (2009). Groups 2009. Markers of inflammation, coagulation, and renal function in HIV-infected adults in the Strategies for Management of ART study and in 2 large population-based studies,
    14. (2009). HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ
    15. (2003). Increased bleeding in HIVpositive haemophiliac patients treated with lopinavir-ritonavir. AIDS
    16. (1998). Intracerebral haemorrhage in AIDS. Cerebrovasc Dis
    17. (2008). Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care STDS
    18. (2004). Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
    19. (2008). Non-AIDS-defining malignancies in HIV. Top HIV Med
    20. (2008). Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Top HIV Med
    21. (2007). Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.
    22. (2000). Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost
    23. (2010). Pharmaceuticals Inc: Aptivus ® (tipranavir) prescribing information.
    24. (2009). Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.
    25. (2007). Platelet activation and atherothrombosis.
    26. (2008). Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.
    27. (2007). Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. Antimicrob Agents Chemother
    28. (2010). The incidence of intra cranial hemorrhage in HIV-infected patients: a case-control study nested
    29. (2009). Update on cardiovascular complications
    30. (2001). Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.